Heron Therapeutics Announces Board and Executive Compensation Changes
Ticker: HRTX · Form: 8-K · Filed: 2024-03-21T00:00:00.000Z
Sentiment: neutral
Topics: board-changes, executive-compensation, governance
Related Tickers: HRTX
TL;DR
Heron Therapeutics adds a new director and updates exec pay. Board changes incoming.
AI Summary
Heron Therapeutics, Inc. announced on March 18, 2024, changes in its board of directors and executive compensation. Specifically, Dr. David P. Ryan was appointed as a new director, and the company also disclosed details regarding compensatory arrangements for its named executive officers.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — The filing reports routine corporate governance changes and executive compensation details, which typically carry low inherent risk.
Key Players & Entities
- Heron Therapeutics, Inc. (company) — Registrant
- Dr. David P. Ryan (person) — Newly appointed director
- March 18, 2024 (date) — Date of earliest event reported
FAQ
Who was appointed as a new director to Heron Therapeutics' board?
Dr. David P. Ryan was appointed as a new director.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is March 18, 2024.
What are the main items disclosed in this 8-K filing?
The filing discloses the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
What is Heron Therapeutics, Inc.'s state of incorporation?
Heron Therapeutics, Inc. is incorporated in Delaware.
What is the business address of Heron Therapeutics, Inc.?
The business address is 4242 Campus Point Court, Suite 200, San Diego, CA 92121.
Filing Stats: 556 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-03-21 16:32:01
Key Financial Figures
- $0.01 — ich registered Common Stock, par value $0.01 per share HRTX The Nasdaq Capital M
Filing Documents
- d801406d8k.htm (8-K) — 23KB
- 0001193125-24-073897.txt ( ) — 143KB
- hrtx-20240318.xsd (EX-101.SCH) — 3KB
- hrtx-20240318_lab.xml (EX-101.LAB) — 18KB
- hrtx-20240318_pre.xml (EX-101.PRE) — 11KB
- d801406d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Heron Therapeutics, Inc. Date: March 21, 2024 /s/ Ira Duarte Ira Duarte Executive Vice President, Chief Financial Officer